Study Title:
A Randomized Controlled Trial Comparing Intraoperative Blood Glucose Control Between
Insulin Drip Versus Insulin Boluses in Adult Cardiac Surgery Patients
Sponsor and Funding:
Sponsor: None
Funding Organization: King Faisal Specialist Hospital & Research Center, Jeddah
Study Site: Single center at King Faisal Specialist Hospital & Research Center, Jeddah
Background and Rationale:
Maintaining optimal blood glucose levels during cardiac surgery is critical for reducing
postoperative complications and improving patient outcomes. Current intraoperative
glucose management strategies vary, with insulin administered either continuously via
infusion (drip) or intermittently as boluses. This trial investigates which method
provides superior glucose control intraoperatively.
Study Design:
This is a prospective, single-center, randomized controlled trial (RCT) with two parallel
arms:
Insulin drip group (continuous infusion)
Insulin bolus group (intermittent dosing)
Objectives:
Primary Objective: To compare the effectiveness of insulin drip versus insulin boluses in
maintaining intraoperative blood glucose within target ranges during adult cardiac
surgery.
Secondary Objectives: To assess the incidence of hypoglycemic events, insulin dose
adjustments, duration of ICU stay, lactate clearance, and wound infection rates at 7- and
30-days post-surgery.
Endpoints:
Primary Endpoint: Rate of severe hypoglycemia during surgery.
Secondary Endpoints: ICU length of stay, postoperative lactate clearance, incidence of
surgical wound infections at 7- and 30-days post-operation.
Participants:
Sample Size: 384 total participants, randomized equally into two groups (192 per group).
Inclusion Criteria: Adults aged over 18 years undergoing cardiac surgery, preoperative
blood glucose between 80-180 mg/dL, with a documented history of diabetes.
Exclusion Criteria: Known intolerance to insulin, severe hepatic dysfunction, recent
hypoglycemic episodes.
Intervention Protocols:
Insulin Drip Group: Continuous intravenous insulin infusion initiated at 2 units/hour,
titrated to maintain target intraoperative glucose levels.
Insulin Bolus Group: Insulin administered as bolus doses every 30 minutes, adjusted based
on glucose monitoring.
Data Collection and Follow-up:
Blood glucose and other relevant clinical parameters are monitored intraoperatively.
Participants are followed postoperatively at 1 week, 1 month, 6 months, and 1 year to
evaluate long-term outcomes and complications. The total anticipated duration of the
trial is 4 years.
Statistical Analysis:
Data analysis will involve calculation of relative risk for hypoglycemia and other
categorical outcomes. Time-to-event data will be analyzed using log-rank tests.
Statistical significance is defined as p < 0.05.